Skip to main content
Contact Us
Subscribe
E-Edition
62°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ironwood Pharmaceuticals, Inc.
< Previous
1
2
Next >
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
February 27, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
February 16, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
February 13, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
February 02, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
January 09, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
November 03, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
October 20, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
September 06, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
September 01, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
August 04, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
July 21, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022
May 25, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022
May 09, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
May 05, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call
April 21, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021
February 17, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call
February 03, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance
January 10, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
December 01, 2021
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
November 04, 2021
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
November 04, 2021
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021
October 25, 2021
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call
October 21, 2021
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
September 02, 2021
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label
August 26, 2021
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance
August 05, 2021
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer
August 03, 2021
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.